Live from the NIH registry
Studies recruiting near Newport News right now
Top 25 of 387 recruiting studies, sorted by proximity — each links to its official registry page
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Previously Treated Non-Small Cell Lung Cancer
Phase 2, Phase 3
Interventional 10,000 participants sought
Peninsula Cancer Institute-Newport News — Newport News, Virginia (9.9 mi)
· Sponsor: SWOG Cancer Research Network
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
B Acute Lymphoblastic Leukemia
Phase 2
Interventional 222 participants sought
Children's Hospital of The King's Daughters — Norfolk, Virginia (22.0 mi)
· Sponsor: National Cancer Institute (NCI)
A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia
Hyperphosphatemia, Chronic Kidney Disease Requiring Chronic Dialysis
Phase 2
Interventional 168 participants sought
DaVita Clinical Research Norfolk — Norfolk, Virginia (22.0 mi)
· Sponsor: R1 Therapeutics
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
PIK3CA Mutation, HER2- Negative Breast Cancer
Phase 3
Interventional 540 participants sought
Virginia Oncology Associates — Norfolk, Virginia (22.0 mi)
· Sponsor: Relay Therapeutics, Inc.
A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
Neovascular Age-related Macular Degeneration
Phase 4
Interventional 188 participants sought
Wagner Kapoor Institute — Norfolk, Virginia (22.0 mi)
· Sponsor: Genentech, Inc.
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
Percutaneous Coronary Intervention, Peripheral Endovascular Intervention
Phase 4
Interventional 6,000 participants sought
TPMG Clinical Research — Newport News, Virginia (9.9 mi)
· Sponsor: Duke University
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Carcinoma, Transitional Cell, Urinary Bladder Neoplasms
Phase 3
Interventional 450 participants sought
USO - Virginia Oncology Associates — Norfolk, Virginia (22.0 mi)
· Sponsor: Eli Lilly and Company
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Phase 2
Interventional 310 participants sought
Site 0295 - Virginia Oncology Associates — Chesapeake, Virginia (23.9 mi)
· Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)
Heart Failure
Phase 3
Interventional 1,500 participants sought
CON-10009, Norfolk, VA — Norfolk, Virginia (22.0 mi)
· Sponsor: Colorado Prevention Center
A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
Obesity, Knee Osteoarthritis (OA)
Phase 3
Interventional 400 participants sought
Health Res of Hampton Roads — Newport News, Virginia (9.9 mi)
· Sponsor: Novo Nordisk A/S
The Vanguard Study: Testing a New Way to Screen for Cancer
Bladder Carcinoma, Breast Carcinoma
N/A
Interventional 24,000 participants sought
Sentara Norfolk General Hospital — Norfolk, Virginia (22.0 mi)
· Sponsor: National Cancer Institute (NCI)
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Urothelial Cancer
Phase 2, Phase 3
Interventional 470 participants sought
Local Institution - 0188 — Norfolk, Virginia (22.0 mi)
· Sponsor: Bristol-Myers Squibb
A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE)
Duchenne Muscular Dystrophy
Phase 3
Interventional 80 participants sought
Children's Hospital of the King's Daughters — Norfolk, Virginia (22.0 mi)
· Sponsor: Solid Biosciences Inc.
AtraUmatic Laparoscopic HerNia Repair Clinical Investigation to Evaluate the Safety and Performance of The ECLIPSIUM System for Mesh Fixation IDE
Hernia
N/A
Interventional 240 participants sought
Tidewater Physicians Multi Specialty Group Hernia Center — Newport News, Virginia (9.9 mi)
· Sponsor: Tissium
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
Prostate Cancer
Phase 3
Interventional 192 participants sought
Hampton University Proton Therapy Institute — Hampton, Virginia (10.9 mi)
· Sponsor: Proton Collaborative Group
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Triple-Negative Breast Cancer
Phase 3
Interventional 1,530 participants sought
Virginia Oncology Associates (VOA) ( Site 8008) — Norfolk, Virginia (22.0 mi)
· Sponsor: Merck Sharp & Dohme LLC
PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis
Generalized Myasthenia Gravis, gMG
Phase 3
Interventional 12 participants sought
Research Site — Norfolk, Virginia (22.0 mi)
· Sponsor: Alexion Pharmaceuticals, Inc.
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
Malignant Glioma
Phase 1, Phase 2
Interventional 132 participants sought
Children's Hospital of The King's Daughters — Norfolk, Virginia (22.0 mi)
· Sponsor: National Cancer Institute (NCI)
A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin
Growth Hormone Deficiency
N/A
Observational 500 participants sought
Ascendis Investigational Site — Norfolk, Virginia (22.0 mi)
· Sponsor: Ascendis Pharma Endocrinology Division A/S
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
Oligometastatic Prostate Cancer (OMPC)
Phase 3
Interventional 450 participants sought
Virginia Oncology Associates — Norfolk, Virginia (22.0 mi)
· Sponsor: Novartis Pharmaceuticals
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
Epithelial Ovarian Cancer, Primary Peritoneal
Phase 2
Interventional 230 participants sought
SCRI - Virginia Oncology Associates — Norfolk, Virginia (22.0 mi)
· Sponsor: TORL Biotherapeutics, LLC
Registry Study for Radiation Therapy Outcomes
Neoplasms
N/A
Observational 50,000 participants sought
Hampton University Proton Therapy Institute — Hampton, Virginia (10.9 mi)
· Sponsor: Proton Collaborative Group
ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack
Cardiovascular Risk, Acute Myocardial Infarction (AMI)
Phase 3
Interventional 10,000 participants sought
Sentara Bayside Hospital — Norfolk, Virginia (22.0 mi)
· Sponsor: Novo Nordisk A/S
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Phase 3
Interventional 736 participants sought
Virginia Oncology Associates — Norfolk, Virginia (22.0 mi)
· Sponsor: BioNTech SE
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Stage III Ovarian Cancer, Stage IV Ovarian Cancer
Phase 3
Interventional 220 participants sought
Virginia Oncology Associates — Norfolk, Virginia (22.0 mi)
· Sponsor: GOG Foundation